Infectious Diseases in Critical Care Medicine

10. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra),
    in patients with rheumatoid arthritis and comparison to anti-TNF-a agents. Clin Exp Rheumatol 2002;
    20(suppl 27):S35–S41.


11. Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active
    rheumatoid arthritis. Arthritis Rheum 2004; 50:1752–1760.


12. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor
    alpha-neutralizing agent. N Engl J Med 2001; 345:1098–1104.


13. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor
    necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter
    active-surveillance report. Arthritis Rheum 2003; 48:2122–2127.


14. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor
    necrosis factor antagonists. Clin Infect Dis 2004; 38:261–265 (correction: 2004; 39:1254–1255).


15. Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann
    Rheum Dis 2005; 64(suppl 4):iv24–iv28.


16. Magro F, Pereira P, Veloso Tavarela F, et al. Unusual presentation of tuberculosis after infliximab
    therapy. Inflamm Bowel Dis 2005; 11:82–84.


17. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis
    factor inhibitor. Clin Infect Dis 2004; 39:295–299.


18. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology
    (Oxford) 2005; 44:714–720.


19. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet
    Infect Dis 2008; 8(10):601–611.


20. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Arthritis Rheum 2008; 58(4):947–952.


21. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis
    and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372–379.


22. Dixon WG, Symmons DP, Lunt M, et al. British Society for Rheumatology Biologics Register Control
    Centre Consortium; Silman AJ, British Society for Rheumatology Biologics Register. Serious infection
    following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from
    interpreting data from observational studies. Arthritis Rheum 2007; 56(9):2896–2904.


23. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis
    patients exposed to tumor necrosis factoraantagonists. Arthritis Rheum 2007; 56(4):1125–1133.


24. Carmona L, Gomez-Reino J, Gonzalez-Gonzalez R. Spanish registry of adverse events of biological
    therapies in rheumatic diseases (BIOBADASER) [Spanish]. Reumatologı ́a Clı ́nica 2005; 1(2):95–104.


25. Centers for Disease Control. Disease listings. Available at: http://www.cdc.gov. Accessed on
    November 4, 2008.


26. Kato K, Nakane A, Minagawa T, et al. Human tumor necrosis factor increases the resistance against
    Listeria infection in mice [abstr]. Med Microbiol Immunol 1989; 178:337–346.


27. Nishikawa S, Miura T, Sasaki S, et al. The protective role of endogenous cytokines in host resistance
    against an intragastric infection with Listeria monocytogenes in mice [abstract]. FEMS Immunol Med
    Microbiol 1996; 16:291–298.


28. Takashima K, Tateda K, Matsumoto T, et al. Role of tumor necrosis factor alpha in pathogenesis of
    pneumococcal pneumonia in mice. Infect Immun 1997; 65:257–260.


29. Van der Poll T, Keogh CV, Buurman WA, et al. Passive immunization against tumor necrosis factor-
    alpha impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med
    1997; 155:603–608.


30. Wellmer A, Gerber J, Ragheb J, et al. Effect of deficiency of tumor necrosis factor alpha or both of its
    receptors onStreptococcus pneumoniaecentral nervous system infection and peritonitis. Infect Immun
    2001; 69:6881–6886.


31. Skerret SJ, Bagby GJ, Schmidt RA, et al. Antibody-mediated depletion of tumor necrosis factor-alpha
    impairs pulmonary host defenses toLegionella pneumophila. J Infect Dis 1997; 176:1019–1028.


32. Makkuni D, Kent R, Watts R, et al. Two cases of serious food-borne infection in patients treated with
    anti-TNF-alpha. Are we doing enough to reduce the risk? Rheumatology (Oxford) 2006; 45:237–238.


33. Katsarolis I, Tsiodras S, Panagopoulous P. Septic arthritis due toSalmonella enteritidisassociated with
    infliximab use. Scand J Infect Dis 2005; 37:304–306.


34. The Food and Drug Administration. Available at: http://www.fda.gov. Accessed on November 1, 2008.


35. Beaman L. Effects of recombinant gamma interferon and TNF on in vitro interactions of human
    mononuclear phagocytes with Coccidioides immitis. Infect Immun 1995; 63:4178–4180.


36. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated
    with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959–1966.

Infections Related to Steroids and Biologics in Critical Care 385